Zusammenfassung
Die präoperative Diagnostik gastrointestinaler Stromatumoren (GIST) zur Bestimmung
der Tumorausdehnung und der Resektabilität entspricht weitgehend der Diagnostik anderer
Tumoren des Gastrointestinaltrakts. Komplexer ist die bildgebende Verlaufsbeobachtung
des Therapieansprechens während einer präoperativen Induktionstherapie mit Imatinib
bei primär nicht im Gesunden resektablen GIST. Die Positronenemissionstomographie
(PET) ist derzeit die Methode der Wahl, um ein (funktionelles) Therapieansprechen
frühzeitig und mit hoher Genauigkeit erkennen zu können, ist aber nur eingeschränkt
verfügbar. Computertomographisch ermittelte (morphologische) Surrogatparameter scheinen
mit dem PET-Ansprechen zu korrelieren, bedürfen jedoch noch der Validierung in prospektiven
Studien.
Abstract
Preoperative diagnostic procedures in patients with gastrointestinal stromal tumors
(GIST) for the assessment of tumor exten-sion and resectability resemble the diagnostic
of other gastrointestinal tumors. More challenging, however, is the evaluation of
treatment response during preoperative induction therapy with imatinib in patients
with primarily irresectable GIST. Positron emission tomography (PET) is the diagnostic
tool of choice with a high sensitivity and specifity for the evaluation of treatment
response but is not readily available. Alternatively, computed tomography (CT) may
provide surrogate parameters which correlate well with the PET response but require
further evaluation in prospective studies.
Schlüsselwörter
Gastrointestinale Stromatumoren - GIST - Diagnostik - Computertomographie - PET
Key words
Gastrointestinal stromal tumor - GIST - diagnosis - computed tomography - PET
Literatur
- 1
De Matteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F.
Two hundred gastrointestinal stromal tumors.
Ann Surg.
2000;
231
51-58
- 2
Miettinen M, Lasota J.
Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical,
and molecular genetic features and differential diagnosis.
Virchov Arch.
2001;
438
1-12
- 3
Miettinen M, Sarlomo-Rikala M, Lasota J.
Gastrointestinal stromal tumours.
Ann Chir Gynaecol.
1998;
87
278-281
- 4
O'Leary T, Berman J.
Gastrointestinal stromal tumors: Answers and Questions.
Hum Pathol.
2002;
33
456-459
- 5
Fletcher C DM, Berman J J, Corless C, Gorstein F, Lasota J, Longley B J, Miettinen M,
O'Leary T J, Remotti H, Rubin B P, Shmookler B, Sobin L H, Weiss S W.
Diagnosis of gastrointestinal stromal tumors: a consensus approach.
Hum Pathol.
2002;
33
459-465
- 6
Graadt van Roggen J F, van Velthuysen M LF, Hogendoorn P CW.
The histopathological differential diagnosis of gastrointestinal stromal tumors.
J Clin Pathol.
2001;
54
96-103
- 7
Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y.
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal
tumours.
J Pathol.
2001;
193
505-510
- 8
Andersson J, Sjögren H, Meis-Kindblom J M, Stenman G, Aman P, Kindblom L.
The complexity of KIT gene mutations and chromosome rearrangements and their clinical
correlation in gastrointestinal stromal (pacemaker cell) tumors.
Am J Pathol.
2002;
160
15-23
- 9
Lasota J, Lasinski M, Sarlomo-Rikala M, Miettinen M.
Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal
stromal tumors and do not occur in leiomyomas.
Am J Surg Pathol.
1999;
154
53-60
- 10
Rubin B P, Singer S, Tsao C, Duensing A, Lux M, Ruiz R, Hibbard M K, Chen C, Xiao S,
Tuveson D A, Demetri G D, Fletcher C DM, Fletcher J A.
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Cancer Res.
2001;
61
8118-8121
- 11
Corless C L, Mc Greevey L, Haley A, Town A, Heinrich M.
KIT mutations are common in incidental gastrointestinal stromal tumors one centimetre
or less in size.
Am J Pathol.
2002;
160
1567-1572
- 12
Heinrich M C, Corless C L, Blanke C, Demetri G D, Joensuu H, von Mehren M, Mc Greevey L S,
Wait C L, Griffith D, Chen C J, Haley A, Kiese B, Druker B, Roberts P, Eisenberg B,
Singer S, Silberman S, Dimitrijevic S, Fletcher C D, Fletcher J A.
KIT mutational status predicts clinical response to STI 571 in patients with metastatic
gastrointestinal stromal tumors (GISTs).
Proc Am Soc Clin Oncol.
2002;
21
2a
- 13
Lux M, Rubin B, Biase T L, Chen C, Maclure T, Demetri G, Xiao S, Singer S, Fletcher D DM,
Fletcher J A.
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
Am J Surg Pathol.
2000;
156
791-795
- 14
Ng E H, Pollock R E, Romsdahl M M.
Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas.
Cancer.
1992;
69
(6)
1334-1341
- 15
Mudan S S, Conlon K C, Woodruff J M, Lewis J J, Brennan M.
Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors
to guide patient selection.
Cancer.
2000;
88
66-74
- 16
Eilber F C, Rosen G, Forscher C, Nelson S D, Dorey F, Eilber F R.
Recurrent gastrointestinal stromal sarcomas.
Surg Oncol.
2000;
9
71-75
- 17
Eilber F C, Rosen G, Forscher C, Nelson S D, Dorey F J, Eilber F R.
Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas.
Ann Surg Oncol.
1999;
6
645-650
- 18
Buemming P, Meis-Kindblom J M, Kindblom L G, Gustavsson B, Thakrar B, Engstrom K,
Ahlman H, Nilsson B E.
Is there an indication for adjuvant treatment with imatinib mesylate in patients with
aggressive gastrointestinal stromal tumors (GISTs)? Abstr 3289.
Proc Am Soc Clin Oncol.
2003;
22
818
- 21 Bauer S, Schütte J.
Gastrointestinale Stromatumoren. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie. Berlin; Springer 2003:
809-826
- 22
Benjamin R S, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R, Bramwell V, Baker L,
Borden E, Demetri G D. for the Sarcoma Intergroup .
Phase III dose-randomized study of imatinib mesylate (STI 571) for GIST: Intergroup
S0033 early results. Abstr 3271.
Proc Am Soc Clin Oncol.
2003;
22
814
- 23
Verweij J, Casali P G, Zalcberg J, Le Cesne A, Reichard P, Blay J Y, Issels R D, Van
Glabbeke M, Donato Di Paola E, Judson I R.
Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal
stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG,
ISG and AGITG. Abstr 3272.
Proc Am Soc Clin Oncol.
2003;
22
814
- 24 Kindblom L G.
Gastrointestinal Stromal Tumors: Current Management and Future Challenges. ASCO Virtual Meeting 2003 http://www. asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-00875-00_
21-0011,00.asp
- 25 Blanke C D.
Gastrointestinal Stromal Tumors: Current Management and Future Challenges. ASCO Virtual Meeting 2003 http://www.asco. org/ac/1,1003,_12-002511-00_18-0023-00_19-00707-00_
21-0011,00.asp
- 26
Van den Abbeele A D, Badawi R D, Cliché J, Janicek J, Tetrault R, Spangler T, Potter A,
Merriam P, Silberman S, Dimitrijevic S, Demetri G D.
18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced
gastrointestinal stromal tumors (GIST).
Proc Am Soc Clin Oncol.
2002;
21
403a
- 27
Kanja J, Bauer S, Schütte J, Bokisch A.
Evaluation of the therapy response with STI 571 in metastatic gastrointestinal stromal
tumor (GIST) by [18F]-FDG-PET.
J Cancer Res Clin Oncol.
2002;
128
(Suppl 1)
S 136
- 28
De Matteo R P, Heinrich M C, El-Rifai W M, Demetri G.
Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Hum Pathol.
2002;
33
466-477
- 29
Van den Abbeele A D. for the GIST Collaborative PET Study .
F18-FDG-PET Provides Early Evidence of Biological Response to STI 571 in Patients
with Malignant Gastrointestinal Stromal Tumors (GIST).
Proc Am Soc Clin Oncol.
2003;
22
(abstr)
1444
- 30
Choi H, Charnsangavej C, Macapinlac H A, Burgess M A, Patel S R, Chen L L, Podoloff D A,
Benjamin R S.
Correlation of computerized tomography (CT) and proton emission tomography (PET) in
patients with metastatic GIST treated at a single institution with imatinib mesylate.
Abstr 3290.
Proc Am Soc Clin Oncol.
2003;
22
819
- 31 Antoch G, Freudenberg L S, Bauer S, Kuehl H, Renzing-Koehler K, Goerges R, Schuette J,
Bockisch A, Debatin J F, Kanja J.
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of Imatinib
(STI 571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med in press
- 32
Choi H, Faria S C, Podoloff D A, Macapinlac H A, Charnsangavej C.
Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST)
with CT and PET: A quantitative analysis.
Radiology.
2002;
225
583
- 33
Chen M YM, Bechtold R E, Savage P D.
Cystic changes in hepatic metastases from gastrointestinal strom tumors.
Am J Roentgenol.
2002;
179
1059-1062
- 34
Van den Abbeele A D, Badawi R D.
Use of positron emission tomography in oncology and its potential role to assess response
to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Eur J Cancer.
2002;
38
(Suppl 5)
S 60-S 65
- 35
Stroobants S, Goeminne J, Seegers M.
18FDG-Positron emission tomography for the early prediction of response in advanced
soft tissue sarcoma treated with imatinib mesylate (Glivec(R)).
Eur J Cancer.
2003;
39
2012-2020
- 36
Reddy M P, Reddy P, Lilien D L.
F-18 FDG PET imaging in gastrointestinal stromal tumor.
Clin Nucl Med.
2003;
28
677-679
- 37
Bauer S, Corless C L, Heinrich M C, Dirsch O, Antoch G, Kanja J, Seeber S, Schutte J.
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression
of KIT.
Cancer Chemother Pharmacol.
2003;
51
261-265
- 38
Young H, Baum R, Cremerius U.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose
and positron emission tomography: review and 1999 EORTC recommendations. European
Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
Eur J Cancer.
1999;
35
1773-1782
- 39
Van den Abbeele A D, Badawi R D, Cliché J P, Janicek M J, Tetrault R, Spangler T,
Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri G D.
18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced
gastrointestinal stromal tumors (GIST).
Proc Am Soc Clin Oncol.
2003;
22
(abstr)
1610
- 40 WHO handbook of reporting results of cancer treatment .Geneva; World Health Organization
Offset Publication No. 48 1979
- 41
Therasse P, Arbuck S G, Eisenhauer E A. et al .
New guidelines to evaluate the response to treatment in solid tumors. European Organization
for Research and Treatment of Cancer, National Cancer Institute of the United States,
National Cancer Institute of Canada.
J Natl Cancer Inst.
2000;
92
205-216
- 42
Hohenberger P, Bauer S, Schneider U, Pinlk D, Dirsch O, Schuette J, Reichardt P.
Tumor resection following imatinib pretreatment in GI stromal tumors.
Proc Am Soc Clin Oncol.
2003;
22
818
- 43
Bauer S, Lang H, Niebel W, Erhardt J, Dirsch O, Gauler T, Bojko P, Seeber S, Flasshove M,
Schütte J.
Resection of residual disease in patients with gastrointestinal stromal tumors after
treatment with imatinib.
Onkologie.
2003;
5
(Suppl.)
32
- 44
Pierie J EN, Muzikansky A, Yeap B Y, Souba W W, Ott M J.
The effect of surgery and outcome of gastrointestinal stromal tumors.
Arch Surg.
2001;
136
383-389
Prof. Dr. J. Schütte
Klinik für Onkologie/Hämatologie, Marien Hospital Düsseldorf, Interdisziplinäres Onkologisches
Zentrum
Rochusstraße 2
40479 Düsseldorf
Phone: + 49-211-4400-2501
Fax: + 49-211-4400-2210
Email: jochen.schuette@uni-essen.de
